Company Filing History:
1 out of 42 
1 out of 113 Years Active: 2018
Title: Michael Bledsoe: Innovator in Companion Animal Health
Introduction
Michael Bledsoe is a notable inventor based in San Diego, California. He has made significant contributions to the field of veterinary medicine, particularly in the treatment of obesity in companion animals. His innovative approach has the potential to improve the health and well-being of pets.
Latest Patents
Michael Bledsoe holds a patent for a method of treating obesity in companion animals. This patent, titled "Modified canine leptin polypeptides and formulations and uses thereof," involves administering a modified canine leptin polypeptide. The invention includes polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide. This method is useful in treating companion animal obesity and other leptin-related disorders.
Career Highlights
Throughout his career, Michael has worked with prominent companies in the veterinary field. He has been associated with Elanco US Inc. and Ambrx, Inc., where he has contributed to advancements in animal health. His work has focused on developing innovative solutions to address health issues in pets.
Collaborations
Michael has collaborated with several professionals in his field. Notable coworkers include Peter Connor Canning and Michael Deguzman. These collaborations have fostered a productive environment for innovation and research in companion animal health.
Conclusion
Michael Bledsoe's contributions to the field of veterinary medicine, particularly through his patent on treating obesity in companion animals, highlight his commitment to improving animal health. His work continues to influence the industry and offers promising solutions for pet owners.